TY - JOUR
T1 - 68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis
AU - Imperiale, Alessio
AU - Poindron, Vincent
AU - Martinez, Matias
AU - Ohlmann, Patrick
AU - Schindler, Thomas H.
AU - El Ghannudi, Soraya
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to F-FDG uptake, which reflects nonspecific leukocyte infiltration, Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive F-FDG PET/CT results.
AB - Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to F-FDG uptake, which reflects nonspecific leukocyte infiltration, Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive F-FDG PET/CT results.
UR - http://www.scopus.com/inward/record.url?scp=85089301758&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000003185
DO - 10.1097/RLU.0000000000003185
M3 - Article
C2 - 32604122
AN - SCOPUS:85089301758
VL - 45
SP - e416-e418
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
SN - 0363-9762
IS - 9
ER -